Strongly


An expression of the live unlimited spirit, stories and voices of the MDA community

FDA Advisory Committee: Data in Support of Translarna ‘Inconclusive’

The FDA yesterday convened a meeting with the PCNS, to review the NDA, for ataluren (brand name Translarna) to treat some forms of DMD. Following a presentation of the data in support of the NDA by PTC Therapeutics the overwhelming majority (10 out of 11) suggested that although it is possible that Translarna may be effective, the data are inconclusive and more work is needed to determine whether, in fact, it is.

Read More